TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06534892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccine
Description: RSVPreF3 OA vaccine administered at different timepoints (revaccination groups) or for the first time (crossover group)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccine
Description: RSVPreF3 OA vaccine administered at different timepoints (revaccination groups) or for the first time (crossover group)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccine
Description: RSVPreF3 OA vaccine administered at different timepoints (revaccination groups) or for the first time (crossover group)
Study: NCT05634902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CME Educational Intervention
Description: The educational materials for physicians include a recorded CME session, a mobile responsive website with the recommended algorithm of care, print materials (posters and note cards) and a dot phrase for dizziness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CME Educational Intervention
Description: The educational materials for physicians include a recorded CME session, a mobile responsive website with the recommended algorithm of care, print materials (posters and note cards) and a dot phrase for dizziness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CME Educational Intervention
Description: The educational materials for physicians include a recorded CME session, a mobile responsive website with the recommended algorithm of care, print materials (posters and note cards) and a dot phrase for dizziness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Developed Educational Materials for Patients
Description: Patient-oriented materials are incorporated into a mobile responsive website with information/instruction about BPPV, and self-management resources; information/instruction on gaze stabilization exercises for vestibular neuritis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Developed Educational Materials for Patients
Description: Patient-oriented materials are incorporated into a mobile responsive website with information/instruction about BPPV, and self-management resources; information/instruction on gaze stabilization exercises for vestibular neuritis
Study: NCT04644367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention
Description: TC classes will be 60 minutes long, offered three times per week over a 12-week period. The participants who receive the TC intervention will be encouraged to attend at minimum two of the three sessions offered per week. The TC classes will follow the same order that will begin with a 5 to 10 minutes warm up, 40 minutes of core activities, and 5 minutes of cool-down. The training intensity and difficulty level of the TC program will gradually proceed from low, moderate, to advance. The classes will be offered in a group setting at a convenient location within a community centre or gymnasium. Alternatively, classes will be offered outdoors in the park or by the canal during the spring-summer months. Due to the COVID-19 situation, additional adaptive measures will be taken using online social platforms such as ZOOM or Hangout to deliver the classes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Physical Activity (control) group
Description: Regular Physical Activity group who will not be receiving the TC intervention
Study: NCT04929665

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two different block and combination of these two blocks
Description: Thoracic paravertebral block, erector spina block, and a combination of paravertebral block and erector spinae block will be applied to the patients under real-time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two different block and combination of these two blocks
Description: Thoracic paravertebral block, erector spina block, and a combination of paravertebral block and erector spinae block will be applied to the patients under real-time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two different block and combination of these two blocks
Description: Thoracic paravertebral block, erector spina block, and a combination of paravertebral block and erector spinae block will be applied to the patients under real-time ultrasound guidance.
Study: NCT06409793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth
Description: A 3-month structured exercise and PA intervention, supported by an exercise specialist, with a 3-month follow-up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: A 3-month structured exercise and PA intervention, supported by an exercise specialist, with a 3-month follow-up
Study: NCT05463198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CM-1600
Description: Subjects undergoing blood donation will be connected to the CM-1600 device.
Study: NCT05538052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
Study: NCT05068648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Wheelchair (MWC) backrest configuration
Description: Wheelchair backrest fitting, postural and functional assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Wheelchair (MWC) backrest configuration
Description: Wheelchair backrest fitting, postural and functional assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Wheelchair (MWC) backrest configuration
Description: Wheelchair backrest fitting, postural and functional assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Wheelchair (MWC) backrest configuration
Description: Wheelchair backrest fitting, postural and functional assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Wheelchair (MWC) backrest configuration
Description: Wheelchair backrest fitting, postural and functional assessment
Study: NCT05241951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured hand-off
Description: Use of standardized checklist to provide synchronous or asynchronous handoff that conveys medication recommendations to the SNF clinical teams

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reconciliation during transitional period
Description: Comprehensive medication reconciliation conducted during transitional period between hospital and SNF, focused on SNF-specific requirements for medication delivery (e.g., stop dates, titration instructions)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional medication monitoring
Description: Review of medication orders during first 7 days of SNF admittance to address barriers to translation of medication orders and appropriate medication delivery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Ad hoc consultation to provide additional clarification to SNF clinical teams
Study: NCT05062473

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Modification Webinars Focused on Hypertension Control
Description: Participation in a 12-week health education telemedicine curriculum
Study: NCT05318326

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: placebo 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yogliptin 400mg group
Description: Yogliptin 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yogliptin 200mg group
Description: Yogliptin 200mg (2 tablet) and placebo 200 mg (2 tablet), Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
Study: NCT06348043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jarvik 2015 LVAD
Description: Medical device used to treat children awaiting heart transplant who fail optimal medical therapy.
Study: NCT06376721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Linperlisib: Phase Ib, oral, 80 mg/d, QD; Phase II, oral, RP2D, QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab for Injection: 200 mg/d, intravenous drip for 30 min (not less than 20 min and not more than 60 min), administered on day 1 of each cycle, observed for 2 hours after infusion. Every 3 weeks is a dosing cycle. Cycle 2 and subsequent cycles of dosing may be administered up to 5 days before or after the day of the scheduled dosing; more than 3 days after the date of the scheduled dosing will be considered a delayed dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Pegaspargase: 2500 IU/m2, intramuscular injection, divided into three places, administered on the first day of each cycle, observed 2 hours after injection for the occurrence of anaphylactic reaction, if there is no anaphylactic reaction before giving other test drugs. Every 3 weeks as a dosing cycle.~Camrelizumab for Injection should not be applied on the same day as Dexamethasonee.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, 20 mg/d, days 1-4. Camrelizumab for Injection should not be applied on the same day as Dexamethasonee.
Study: NCT05643664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prosthetics of the abdominal aorta
Description: aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prosthetics of the abdominal aorta after determining the safe zones of clamping
Description: aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology. Before surgery, multispiral computed tomography data is evaluated using artificial intelligence and safe zones of aortic and arterial clampings are determined. Intraoperatively, clamping is performed in the settlement zones.
Study: NCT04747405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapy group
Description: therapy group of maximum 8 people repeated twice
Study: NCT06444438

Intervention type: DIAGNOSTIC_TEST
Intervention: subarachnoid hemorrhage
Description: CT presented subarachnoid hemorrhage
Study: NCT06606028

Intervention type: PROCEDURE
Intervention: Blood Specimen Collection
Description: Approximately 20 mL of peripheral blood (10 mL per tube, x 3 Streck tubes) will be drawn at each time point

Intervention type: PROCEDURE
Intervention: Blood Specimen Collection
Description: Approximately 20 mL of peripheral blood (10 mL per tube, x 3 Streck tubes) will be drawn at each time point

Intervention type: PROCEDURE
Intervention: Tumor Tissue Collection
Description: Formalin-fixed paraffin embedded tumor tissue samples (tissue blocks of 12 x 10 millimeter (mm) unstained slides) derived from biopsy or surgical resection will be collected at screening

Intervention type: PROCEDURE
Intervention: Tumor Tissue Collection
Description: Formalin-fixed paraffin embedded tumor tissue samples (tissue blocks of 12 x 10 millimeter (mm) unstained slides) derived from biopsy or surgical resection will be collected at screening

Intervention type: OTHER
Intervention: Medical Record Review
Description: Medical records will be reviewed to collect standard of care p16 staining by immunohistochemistry and/or high-risk human papillomavirus (HPV) DNA or RNA testing that is performed as part of standard of care

Intervention type: OTHER
Intervention: Medical Record Review
Description: Medical records will be reviewed to collect standard of care p16 staining by immunohistochemistry and/or high-risk human papillomavirus (HPV) DNA or RNA testing that is performed as part of standard of care
Study: NCT05710432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quasi-Isometric Neck Flexion
Description: Patients will be asked to minimally lift their head from the pillow generating a quasi-isometric neck contraction (2 sets of 6-10 flexions).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quasi-Isometric Neck Flexion
Description: Patients will be asked to minimally lift their head from the pillow generating a quasi-isometric neck contraction (2 sets of 6-10 flexions).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Patients will be asked to complete 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load).~During each IMT and neck flexion maneuver ultrasound measurements will be performed (measurements of the diaphragm, sternocleidomastoid, parasternal intercostal, internal oblique \[IO\], external oblique \[EO\], transversus abdominis \[TrA\] and rectus abdominis \[RA\] will be taken) and, during the entire period, sEMG monitoring of the target muscles (diaphragm, sternocleidomastoid, parasternal intercostal and EO) will be continued.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Patients will be asked to complete 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load).~During each IMT and neck flexion maneuver ultrasound measurements will be performed (measurements of the diaphragm, sternocleidomastoid, parasternal intercostal, internal oblique \[IO\], external oblique \[EO\], transversus abdominis \[TrA\] and rectus abdominis \[RA\] will be taken) and, during the entire period, sEMG monitoring of the target muscles (diaphragm, sternocleidomastoid, parasternal intercostal and EO) will be continued.
Study: NCT06386328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-378, QD, PO
Description: CKD-378, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-378, QD, PO
Description: CKD-378, QD, PO
Study: NCT04854330

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone monoesters
Description: A Kme commercially available supplement will be given to the participants in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.30 ml.kg-1 body mass) and will be ingested with water and cherry-flavoured stevia in a total volume of 100 ml.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo condition, participants will consume 100 ml of water and cherry-flavoured stevia followed by the same 20 ml calorie-free sparkling spring water.
Study: NCT04680962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MabionCD20 (candidate biosimilar to rituximab)
Description: Intravenous infusion, 10 mg/ml concentrate, 500 ml
Study: NCT06055634

Intervention type: GENETIC
Intervention: genotyping of SIRT1 in chronic obstructive patients
Description: genotyping of SIRT1 in chronic obstructive patients

Intervention type: GENETIC
Intervention: genotyping of SIRT1 in chronic obstructive patients
Description: genotyping of SIRT1 in chronic obstructive patients

Intervention type: GENETIC
Intervention: genotyping of SIRT1 in chronic obstructive patients
Description: genotyping of SIRT1 in chronic obstructive patients
Study: NCT05198648

Intervention type: OTHER
Intervention: Trigeminal cardiac reflex
Description: Trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.

Intervention type: OTHER
Intervention: Non-trigeminal cardiac reflex
Description: No trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
Study: NCT05426811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib:120mg/d，Po，qd,d1-d21，Every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed:3mg/㎡，ivgtt，d1，Every 3 weeks
Study: NCT05852639

Intervention type: DEVICE
Intervention: Ultrasound
Description: Routine obstetric ultrasound will be done at term (at 37 weeks gestation): to confirm gestational age, assess fetal weight and amniotic fluid index and to exclude fetal anomalies.Doppler study and cerebroplacental ratio assessment will be done at 37 weeks gestation and repeated every two weeks

Intervention type: DEVICE
Intervention: Ultrasound
Description: Routine obstetric ultrasound will be done at term (at 37 weeks gestation): to confirm gestational age, assess fetal weight and amniotic fluid index and to exclude fetal anomalies.Doppler study and cerebroplacental ratio assessment will be done at 37 weeks gestation and repeated every two weeks
Study: NCT05444140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: The health coaching programme includes four monthly health coaching sessions for three months.
Study: NCT05995444

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epetraborole and matching placebo
Description: Treatment A (Therapeutic): 500 mg epetraborole (2 x 250 mg tablets) and epetraborole matching-placebo (6 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epetraborole
Description: Treatment B (Supratherapeutic): 2000 mg epetraborole (8 x 250 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epetraborole
Description: Treatment B (Supratherapeutic): 2000 mg epetraborole (8 x 250 mg tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment C (Placebo control): Epetraborole matching-placebo (8 tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Treatment D (Positive control): 400 mg moxifloxacin (1 x 400 mg tablet)
Study: NCT04659993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemental Health Sessions, Support Groups and Questionnaires
Description: Participants will complete initial online questionnaires lasting about 25-30 minutes as well as attend weekly support group meetings online. After 4 weeks, participants will complete seven online follow-up questionnaires that should take no longer than 30 minutes and again at the end of the study.
Study: NCT04680962

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabionCD20 (candidate biosimilar to rituximab)
Description: Intravenous infusion, 10 mg/ml concentrate, 500 ml
Study: NCT05217914

Intervention type: DRUG
Intervention: Copanlisib (BAY80-6946)
Description: Copanlisib for treatment of relapse/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL)
Study: NCT04680962

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera®
Description: Intravenous infusion, 10 mg/ml concentrate, 500 ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan®
Description: Intravenous infusion, 10 mg/ml concentrate, 500 ml
Study: NCT04784962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revitive Medic Neuromuscular Stimulation Device
Description: Usage of the Revitive NMES device - 1-6 sessions daily (30 minutes per session).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Revitive Medic Neuromuscular Stimulation Device (Sham)
Description: Usage of the Sham Revitive NMES device - 1-6 sessions daily (30 minutes per session)
Study: NCT06329479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for Insomnia (CBT-I)
Description: A psychoeducational and evidence-based skills and strategies course for insomnia delivered online over four lessons through ThisWayUp. This will be completed during an 8-week feasibility trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: Daily bright light therapy for 30 minutes on waking delivered using the Lumie-L light box during an 8-week feasibility trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualised activity plan
Description: An individualised activity plan is created at baseline and adjusted weekly aiming to increased daytime physical activity and reduce sedentary behaviours. The activity plan takes into consideration personal interests, perceived barriers to activity and develops an activity plan using Specific Measureable Achievable Realistic and Timely (SMART) goals. This will take place during an 8-week feasibility trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clincial review
Description: Two clinical reviews will take place during an 8-week feasibility trial and consider uncontrolled symptoms, medication and blood test abnormalities which may impact on rest and physical activity levels
Study: NCT06005584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation - High Frequency SCS
Description: High Frequency-SCS consists of delivering electrical stimulation at frequencies equal to or greater than 1kHz.~This intervention will last up to 6 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation - Burst SCS
Description: Burst SCS consists of closely spaced, high frequency stimuli delivered to the spinal cord.~This intervention will last up to 6 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spinal Cord Stimulation - Sham SCS
Description: This intervention will last up to 6 weeks.
Study: NCT05034640

Intervention type: PROCEDURE
Intervention: Conventional multiport thoracoscopic surgery
Description: Use 2 or more incisions for multiple instrument entry during the surgery and chest tube placement at the end of the operation.

Intervention type: PROCEDURE
Intervention: Single port site thoracoscopic surgery
Description: Using only 1 incision for multiple instrument entry during the surgery and chest tube placement at the end of the operation. Single port - GelPOINT Mini® port (Applied Medical, Rancho Santa Margarita, California, USA)
Study: NCT05739773

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: five-element music therapy
Description: music therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: five-element music therapy
Description: music therapy